A new revolutionary product for weight loss medication
CagriSema is a combination of semaglutide and a new amylin analogue, cagrilintide, administered subcutaneously once a week.
According to the findings, following 32 weeks of treatment, subjects who received CagriSema attained a 2.18%-points numerically greater decline in HbA1c versus 1.79%-points and 0.93%-points for semaglutide and cagrilintide alone, respectively.
Subjects in the CagriSema arm had a 15.6% numerically greater decline in body weight versus 5.1% and 8.1% with semaglutide and cagrilintide, respectively.
CagriSema was found to be safe and well-tolerated in the trial.
The results indicate that CagriSema reduces blood sugar more than semaglutide alone, and the weight loss seen in the trial confirms the substantial weight lowering potential of CagriSema.Researchers speculate that weight loss with CagriSema (Cagrilintide Semaglutide) may approach 23% to 30% which is probably the highest degree of weight loss associated with any of the medical therapies.
Login 
Inquiry List
